| __timestamp | Axsome Therapeutics, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 4279200 | 1513000 |
| Thursday, January 1, 2015 | 6776987 | 12573000 |
| Friday, January 1, 2016 | 21199860 | 42238000 |
| Sunday, January 1, 2017 | 19957616 | 69800000 |
| Monday, January 1, 2018 | 23495055 | 113773000 |
| Tuesday, January 1, 2019 | 53647067 | 179362000 |
| Wednesday, January 1, 2020 | 70244579 | 266946000 |
| Friday, January 1, 2021 | 58060725 | 438633000 |
| Saturday, January 1, 2022 | 57947447 | 461645000 |
| Sunday, January 1, 2023 | 97944000 | 387332000 |
| Monday, January 1, 2024 | 187077000 | 320653000 |
Cracking the code
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Axsome Therapeutics, Inc. and CRISPR Therapeutics AG have demonstrated contrasting trajectories in their R&D investments.
From 2014 to 2023, CRISPR Therapeutics AG consistently outpaced Axsome Therapeutics, with R&D expenses peaking at nearly 462% higher in 2022. This trend underscores CRISPR's aggressive pursuit of cutting-edge gene-editing technologies. Meanwhile, Axsome's R&D spending surged by over 2,000% from 2014 to 2023, reflecting its strategic focus on developing novel therapies for central nervous system disorders.
The data reveals a fascinating narrative of two companies navigating the biotech landscape with distinct strategies. As the industry evolves, these R&D investments will likely play a pivotal role in shaping the future of medical breakthroughs.
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Axsome Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
Research and Development Investment: Axsome Therapeutics, Inc. vs Alpine Immune Sciences, Inc.
Analyzing R&D Budgets: Verona Pharma plc vs CRISPR Therapeutics AG
Research and Development Investment: Ultragenyx Pharmaceutical Inc. vs CRISPR Therapeutics AG
Viking Therapeutics, Inc. or CRISPR Therapeutics AG: Who Invests More in Innovation?
Comparing Innovation Spending: CRISPR Therapeutics AG and Veracyte, Inc.
Research and Development: Comparing Key Metrics for CRISPR Therapeutics AG and Bausch Health Companies Inc.
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Geron Corporation
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc.